Updates on World Health Organization classification and staging of esophageal tumors: implications for future clinical practice

Liu

2022

Preprint

Background: Esophageal adenosquamous carcinoma (EASC) is a rare disease. The biological behavior and treatment of this malignancy are not well studied. Methods: Data from 56 patients with EASC who underwent esophagectomy were retrospectively analyzed and compared with 5028 patients with esophageal squamous cell carcinoma (ESCC). The impact of clinicopathological factors on the survival of patients with EASC was analyzed. The survival differences between patients with EASC and ESCC were also compared. Results: There were 43 males and 13 females with a mean age of 59.7 ± 1.3 years (range, 39-79 years). Only one of the 43 patients who received preoperative esophagoscopic biopsy was diagnosed with EASC. The median survival time for patients with EASC was 32.0 months, and the 1-, 3- and 5-year overall survival rates were 78.3%, 46.1% and 29.6%, respectively. Resection margin, pN category, and adjuvant chemotherapy were found to be independent predictors. After 1:1 propensity score matching, the 5-year overall survival rate of 29.6% for patients with EASC was similar to that of 42.5% for patients with ESCC (P=0.179). Conclusions: EASC is a rare disease and is easily misdiagnosed by esophagoscopic biopsy. The prognosis of EASC was similar to that of ESCC. Postoperative adjuvant chemotherapy may improve the survival of patients with EASC after esophagectomy.

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Surgical Resection for Esophageal Adenosquamous Carcinoma: an Analysis of 56 Cases

Liu

2022

Preprint

“…Among gastrointestinal malignancies, the oesophageal cancer is unique. It embodies two distinct major histopathologic types: squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) [ 115 ]. Other malignancies involving the oesophagus, such as primary oesophageal melanoma, leiomyosarcoma, or lymphoma are much rarer than the ESCC and adenocarcinoma.…”

Section: Cancers Of the Gastrointestinal Tractmentioning

confidence: 99%

Extracellular Vesicles as a Novel Liquid Biopsy-Based Diagnosis for the Central Nervous System, Head and Neck, Lung, and Gastrointestinal Cancers: Current and Future Perspectives

Testa

Venturelli

Brizzi

2021

Cancers

Early diagnosis, along with innovative treatment options, are crucial to increase the overall survival of cancer patients. In the last decade, extracellular vesicles (EVs) have gained great interest in biomarker discovery. EVs are bilayer lipid membrane limited structures, released by almost all cell types, including cancer cells. The EV cargo, which consists of RNAs, proteins, DNA, and lipids, directly mirrors the cells of origin. EVs can be recovered from several body fluids, including blood, cerebral spinal fluid (CSF), saliva, and Broncho-Alveolar Lavage Fluid (BALF), by non-invasive or minimally invasive approaches, and are therefore proposed as feasible cancer diagnostic tools. In this review, methodologies for EV isolation and characterization and their impact as diagnostics for the central nervous system, head and neck, lung, and gastrointestinal cancers are outlined. For each of these tumours, recent data on the potential clinical applications of the EV’s unique cargo, alone or in combination with currently available tumour biomarkers, have been deeply discussed.

“…Esophageal adenosquamous carcinoma (EASC) is a rare disease that contains both squamous cell carcinoma and adenocarcinoma components with a well-defined border [ 1 , 2 ]. According to a large series, EASC accounts for approximately 1% of all esophageal carcinomas [ 3 – 6 ].…”

Section: Introductionmentioning

confidence: 99%

Surgical resection for esophageal adenosquamous carcinoma: an analysis of 56 cases

2022

Background Esophageal adenosquamous carcinoma (EASC) is a rare disease. The biological behavior and treatment of this malignancy are not well studied. Methods Data from 56 patients with EASC who underwent esophagectomy were retrospectively analyzed and compared with 5028 patients with esophageal squamous cell carcinoma (ESCC). The impact of clinicopathological factors on the survival of patients with EASC was analyzed. The survival differences between patients with EASC and ESCC were also compared. Results There were 43 males and 13 females with a mean age of 59.7 ± 1.3 years (range, 39–79 years). Only 1 of the 43 patients who received preoperative esophagoscopic biopsy was diagnosed with EASC. The median survival time for patients with EASC was 32.0 months, and the 1-, 3-, and 5-year overall survival rates were 78.3%, 46.1%, and 29.6%, respectively. Resection margin, pN category, and adjuvant chemotherapy were found to be independent predictors. After 1:1 propensity score matching, the 5-year overall survival rate of 29.6% for patients with EASC was similar to that of 42.5% for patients with ESCC (P = 0.179). Conclusions EASC is a rare disease and is easily misdiagnosed by esophagoscopic biopsy. The prognosis of EASC was similar to that of ESCC. Postoperative adjuvant chemotherapy may improve the survival of patients with EASC after esophagectomy.